REGENXBIO Inc. Contract Liability (Deferred Revenue)
REGENXBIO Inc. (RGNX) had Contract Liability (Deferred Revenue) of $9.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $9.88M.
- 2026-03-31: Contract with Customer, Liability, Current $5.92M.
- 2025-12-31: Contract with Customer, Liability, Current $10.45M.
- 2025-09-30: Contract with Customer, Liability, Current $13.20M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $9.88M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.92M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $10.45M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $13.20M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $13.98M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $13.59M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $115.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $144.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $21.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $13.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $148.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $442.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $448.00K 10-Q · filed 2023-08-02 |
| 2023-03-31 | $1.31M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $1.83M 10-K · filed 2024-02-27 |
| 2022-09-30 | $5.90M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $6.64M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $3.33M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $3.33M 10-K · filed 2023-02-28 |
| 2021-09-30 | $395.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $395.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $395.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $449.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $449.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $450.00K 10-Q · filed 2020-08-06 |
| 2019-03-31 | $600.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $600.00K 10-K · filed 2020-02-26 |
| 2018-09-30 | $600.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $600.00K 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |